NCT02507583 2025-05-07
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Thomas Jefferson University
Phase 1 Completed
Thomas Jefferson University
DNAtrix, Inc.
Ohio State University Comprehensive Cancer Center
Tampa General Hospital